Related Experiment Video
Updated: Jun 16, 2026
Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens
Published on: February 14, 2011
Omalizumab: when the non-responder is a late-responder
F Menzella1, N Facciolongo, C Castagnetti
1Department of Respiratory Diseases, S. Maria Nuova Hospital - Reggio Emilia, Italy.
Unlabelled:
Omalizumab is an anti-IgE monoclonal antibody available since 2006 for the treatment of GINA step 4 asthma. We studied a 41-year old male who has been suffering from severe steroid-resistant asthma with severe co-morbidity and treated with Omalizumab. He was found to be non-responder to the treatment until the 48th week, starting from which we began to see a distinct improvement in the symptoms and all the correlated parameters, in addition to remission of the co-existent allergy to milk.
Conclusions:
we wish to point out the late response to Omalizumab, which occurred way beyond the times envisaged in literature. It seems possible that some patients are late responders to the drug.
